Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement
- PMID: 39934019
- DOI: 10.1016/j.ard.2025.01.023
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statement
Abstract
Objective: This systematic literature review (SLR) on efficacy outcomes was performed to inform the 2024 update of the expert consensus statement on the treatment of immune-mediated inflammatory diseases (IMIDs) with Janus kinase inhibitors (JAKi).
Methods: An update of the 2019 SLR was performed in MEDLINE, Embase, and the Cochrane Library. For efficacy, randomised, placebo (PLC)- or active-controlled trials on all JAKi investigated in IMIDs, as well as cohort and claims data for conditions where such studies were not available, were included.
Results: In total, 10,556 records were screened, and 182 articles were included in the final analysis, investigating 21 JAKi in 51 IMIDs. Forty-three phase 2 and 59 phase 3 trials as well as 9 strategic trials and 72 pilot or cohort studies and case series were considered. JAKi demonstrated efficacy both in PLC-controlled trials as well as in head-to-head comparisons against active comparators, with 93 of 102 randomised controlled trials (RCTs) meeting their primary endpoints. Since 2019, 8 JAKi have received approval by the Federal Drug Agency and the European Medicine Agency for treatment of 11 IMIDs; of these, for 2, no approved disease-modifying antirheumatic drug (DMARD) therapy had previously been available.
Conclusions: JAKi are effective for treating IMIDs, and various compounds have recently been approved. The impact of Janus kinase (JAK) selectivity for distinct JAK-STAT pathways needs further investigation, and few data are also available on sustained disease control upon tapering or withdrawal or on the optimal strategic placement of JAKi in international treatment algorithms.
Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Competing interests VK received speaker fees from Eli Lilly and AstraZeneca. JSS received grants from AbbVie, AstraZeneca, Eli Lilly, and Galapagos and speaker or consultancy fees from AbbVie, Amgen, Anada, Astro Pharma, BMS, Celltrion, Chugai, Eli Lilly, Gilead, Immunovant, MSD, Novartis, Pfizer, Roche, R-Pharma, Samsung, Sanofi, and Union Chimique Belge (UCB). PN received grants from AbbVie, BMS, Pfizer, Novartis, Eli Lilly, UCB, and Janssen and speaker or consultancy fees from Eli Lilly, Novartis, AbbVie, Pfizer, BMS, Novartis, Janssen, and UCB. DA received grants from Eli Lilly and Galapagos and speaker or consultancy fees from AbbVie, Gilead, J&J, Eli Lilly, MSD, Novartis, and Sandoz. KW received grants from BMS and Pfizer and speaker or consultancy fees from BMS, Pfizer, AbbVie, UCB, Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and Moderna. TD received grants from BMS, Eli Lilly, and J&J and speaker or consultancy fees from BMS, Eli Lilly, J&J, Pfizer, Novartis, Roche/GNE, and Remegen. RF received grants from AbbVie, BMS, Galvani, GSK, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, and UCB and consultancy fees from AbbVie, Almirall, Artiva, Biotherapeutics, Atomwise, Biohaven, Pharmaceuticals, BMS, Cyoxone, Deep Cure, Dren Bio, Galvani, Gates Bio, Gilead, GSK, Halia, Immunovant, ImmuneMed, InventisBio, Istesso, Janssen, Janux, Eli Lilly, Monte Rosa, Novartis, Overland, Pfizer, Spyre, Synact, Teijin Pharma, TPG, UCB, Vyne, and Xencor. YT received grants from Mitsubishi Tanabe, Eisai, Chugai, and Taisho and speaker or consultancy fees from Eli Lilly, AstraZeneca, AbbVie, Gilead Sciences, Chugai, Boehringer Ingelheim, GSK, Eisai, Taisho, BMS, and Pfizer. XB received speaker or consultancy fees from AbbVie, Alphasigma, Amgen, BMC, Cesas, Celltrion, Galapagos, Janssen, Eli Lilly, Moonlake, Novartis, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB, and Zuellig. IBM received grants from AbbVie, Amgen, BMS, Causeway Therapeutics, Cabaletta, Dextera, Eli Lilly, Gilead, Janssen, Novartis, Montai, Pfizer, Sanofi Regeneron, UCB, Compugen, AstraZeneca, and Moonlake and speaker or consultancy fees from AbbVie, Amgen, BMS, Causeway Therapeutics, Cabaletta, Dextera, Eli Lilly, Gilead, Janssen, Novartis, Montai, Pfizer, Sanofi Regeneron, UCB Pharma, Compugen, AstraZeneca, and Moonlake. MT received grants from Albireo, Alnylam, Cymabay, Falk Pharma, Genentech, Gilead, Intercept, MSC, Takeda, and UltraGenyx and speaker or consultancy fees from AbbVie, Agomab, Albireo, BiomX, Boehringer Ingelheim, Chemomab, Cymabay, Falk, Gilead, Genit, Hightide, Intercept, Ipsen, Janssen, LoopLab, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, Shire, and Siemens. NS received grants from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics and speaker or consultancy fees from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Menarini-Ricerche, Novartis, Novo Nordish, Pfizer, Roche Diagnostics, and Sanofi. MdW received speaker fees from Evidera, UCB, Zürich Hospital, and the REMEDI Consortium. AK received speaker or consultancy fees from AbbVie, Eli Lilly, Gilead, Janssen, UCB, Galapagos, MSD, Novartis, and Pfizer. JP and JWS have nothing to declare.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
